Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Global type 1 diabetes market is estimated to be valued at USD 16.97 Bn in 2025 and is expected to reach USD 26.22 Bn by 2032 ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Novo Nordisk (NYSE:NVO) reported strong first-quarter results, but lowered its full-year guidance due to ...

City Hall chiefs point finger at poor work-life balance as stark health data emerges, prompting a new initiative to create a ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

Cholesterol tests check the components of fat in your blood and compare them to normal ranges. Your clinician might also use ...

Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due to what Novo says is illegal compounding of ...

A man is suing the manufacturers of Ozempic, alleging the diabetes drug caused him to go blind. The medication, containing ...